Form 3 Filing for Jill M. Quigley at Chemomab Therapeutics Ltd.

This filing, a Form 3, details the initial ownership of securities by Jill M. Quigley, a director at Chemomab Therapeutics Ltd. The report, filed on March 25, 2026, covers the period ending March 18, 2026. Quigley holds direct ownership of several stock options to purchase American Depositary Shares (ADS). These options have varying exercise dates, expiration dates, and conversion prices. Specifically, options granted on June 16, 2022, June 14, 2023, and June 16, 2024, are fully vested and exercisable. Additionally, options granted on June 16, 2026, are also reported. The total number of underlying ADSs subject to these options is 11,616. The filing notes reliance on temporary relief for foreign private issuers regarding the filing deadline.